For this study, we included 87 of the 101 patients with CSNB from the 2013 study by Bijveld et al.,
10 and an additional 47 patients examined at our clinic over the last years. We included patients who showed clear phenotypic characteristics (including a pathognomonic ERG for CSNB1 or CSNB2) along with genotypic traits linked to CSNB.
10 Additional inclusion criteria were the availability of refraction data and no history of any myopia control treatment. In four patients with
TRPM1 mutations, only one heterozygous mutation was identified. However, because these patients exhibited an evident CSNB phenotype (including a pathognomonic ERG) we included them in our study. Patients with
CABP4 mutations were excluded. In the past,
CABP4 mutations have been described as a cause of autosomal recessive CSNB2. However, because these patients have a different phenotype, including photophobia, absence of night blindness, and mainly hyperopia,
CABP4 mutations are now regarded as a cause of cone-rod synaptic disorder but not as a form of CSNB.
24 Most of the available data were obtained during childhood (see
Supplementary Fig. S1), and because myopization due to growth of the eye is most likely to stabilize before the age of 21 years,
25 we also excluded 14 datapoints (7 patients) at an age > 21 years. Furthermore, we excluded one (the first) measurement of a 5-year-old patient with CSNB1 with
GRM6 mutations, because the patient's myopia showed an unlikely change of approximately 3.5 diopters (D) for both eyes in 5 months’ time (from −9.5 D to −6 D). This resulted in a total of 295 refraction measurements in 127 patients with CSNB (48 with CSNB1 and 79 with CSNB2) at various ages during childhood. The distribution in genes, male–female ratio, and mean age at first visit of these patients are shown in
Table 1. An overview of the genetic mutations found in our study group is presented in
Supplementary Table S1.